Celyad Oncology SA

CYAD

BE0974260896

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 12:19:20 10/06/2026 BST			5-day change	1st Jan Change
0.2600 ^EUR	0.00%		-8.45%	+52.94%

04-15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating

Published on 01/11/2022 at 05:12 pm GMT - Modified on 01/11/2022 at 05:13 pm GMT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Celyad Oncology SA

04-15	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
04-02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/09/25	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/09/25	Celyad Oncology announces research facility divestiture	RE
28/09/25	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/09/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/08/25	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/07/25	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
27/07/25	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/06/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/06/25	Celyad Oncology Announces Strategic Review	CI
02/04/25	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/02/25	Celyad: share price soars on encouraging data
18/02/25	Celyad Oncology Announces the Publication of the Preclinical and Clinical Data of CYAD-211 Providing Proof-Of-Concept of Its miRNA-Based shRNA Platform	CI
17/09/24	Celyad Oncology Names New CEO to Start in October	MT

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company